A study in JAMA Oncology has found that chemotherapy for patients with end-stage cancer was associated with worse quality of life near death while they still retained their ability to perform many life functions.
Increased attention is now being afforded to quality of life for patients with advanced-stage disease. CMS recently announced that hospices have been selected to participate in the Medicare Care Choices Model so dually eligible beneficiaries can receive supportive care services provided by a hospice while undergoing curative treatment. Now, an article published in JAMA Oncology underscores the need for these efforts to improve quality of life, especially for cancer patients. The study found that chemotherapy for patients with end-stage cancer was associated with worse quality of life near death while they still retained their ability to perform many life functions.
In a related commentary, Charles D. Blanke, MD, and Erik. K. Fromme, MD, of the Oregon Health & Science University, Portland, write: “These data from Prigerson and associates suggest that equating treatment with hope is inappropriate. Even when oncologists communicate clearly about prognosis and are honest about the limitations of treatment, many patients feel immense pressure to continue treatment. … At this time, it would not be fitting to suggest guidelines must be changed to prohibit chemotherapy for all patients near death without irrefutable data defining who might actually benefit, but if an oncologist suspects the death of a patient in the next six months, the default should be no active treatment,” the author concludes.
The American Journal of Managed Care recently published an entire issue on palliative care, inviting payers, health policy experts, as well as providers of palliative care to address the topic.
Review: One-Shot Etranacogene Dezaparvovec Represents Game-Changing Gene Therapy for Hemophilia B
May 3rd 2024More than 20 years of gene therapy clinical research have led to etranacogene dezaparvovec’s use in hemophilia B, according to authors of a recent review—and it takes its place in a line of current and potentially many future genomic medicines for a range of diseases.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Shelly Lanning on How Employers Can Reduce Costs by Bridging Gaps in Women's Health Care
May 3rd 2024In a presentation at the Greater Philadelphia Business Coalition on Health Women’s Health Summit, Shelly Lanning, cofounder and president of Visana Health, addressed the need for comprehensive approaches in women’s health care and their coverage options.
Read More